Group One Trading
VERV

Group One Trading’s Verve Therapeutics VERV Stock Holding History

Group One Trading’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-40,400
Closed -$454K – 9214
2025
Q2 		$454K Buy
40,400
+28,200
+231% +$161K ﹤0.01% 3519
2025
Q1 		$55.8K Buy
12,200
+6,300
+107% +$42.2K ﹤0.01% 5076
2024
Q4 		$33.3K Sell
5,900
-2,300
-28% -$13K ﹤0.01% 5368
2024
Q3 		$39.7K Buy
8,200
+5,500
+204% +$31.9K ﹤0.01% 4797
2024
Q2 		$13.2K Sell
2,700
-500
-16% -$3.14K ﹤0.01% 5485
2024
Q1 		$42.5K Buy
3,200
+2,300
+256% +$30.5K ﹤0.01% 4846
2023
Q4 		$12.5K Sell
900
-100
-10% -$1.24K ﹤0.01% 6064
2023
Q3 		$13.3K Buy
+1,000
New +$16.1K ﹤0.01% 6173
2023
Q1 		– Sell
-2,000
Closed -$38.7K – 8015
2022
Q4 		$38.7K Buy
2,000
+1,000
+100% +$26.5K ﹤0.01% 5186
2022
Q3 		$34K Buy
+1,000
New +$31.9K ﹤0.01% 5717
2022
Q2 		– Sell
-600
Closed -$14K – 8576
2022
Q1 		$14K Buy
+600
New +$17.1K ﹤0.01% 7012

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Group One Trading's VERV Position: Q3 2025 in Review

Group One Trading sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 45,160 shares — an estimated $507K sold.

Group One Trading first reported a position in VERV in Q4 2022 and held it in 8 quarters. The position peaked at $507K in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Group One Trading reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Group One Trading sold 45,160 Verve Therapeutics shares in Q3 2025, an estimated $507K.
  • Group One Trading first reported a position in Verve Therapeutics in Q4 2022 and held it in 8 quarters.
  • Group One Trading's Verve Therapeutics position peaked at $507K in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Group One Trading's 13F filing for Q3 2025, filed 12 Nov 2025.